The Ca^(2+)-activated chloride channel ANO1/TMEM16A:An emerging therapeutic target for epithelium-originated diseases?  

作　　者：Yani Liu Zongtao Liu KeWei Wang 

机构地区：[1]Department of Pharmacology,School of Pharmacy,Qingdao University Medical College,Qingdao 266073,China [2]Institute of Innovative Drugs,Qingdao University,Qingdao 266021,China [3]Department of Clinical Laboratory,Qingdao Third People's Hospital,Qingdao 266041,China

出　　处：《Acta Pharmaceutica Sinica B》2021年第6期1412-1433,共22页药学学报（英文版）

基　　金：supported by grants from the National Natural Science foundation of China (81573410);the Ministry of Science and Technology of China (2018ZX09711001-004-006);Shandong Provincial Medicine and Health Technology Development Plan (2019WS145, China);Medical Research Guidance Plan of Qingdao Municipal Health Committee (2019-WJZD091, China);Qingdao Excellent Young Medical Talent Training Project。

摘　　要：Anoctamin 1(ANO1) or TMEM16 A gene encodes a member of Ca^(2+) activated Cl^(-) channels(CaCCs) that are critical for physiological functions,such as epithelial secretion,smooth muscle contraction and sensory signal transduction.The attraction and interest in ANO1/TMEM16 A arise from a decade long investigations that abnormal expression or dysfunction of ANO1 is involved in many pathological phenotypes and diseases,including asthma,neuropathic pain,hypertension and cancer.However,the lack of specific modulators of ANO1 has impeded the efforts to validate ANO1 as a therapeutic target.This review focuses on the recent progress made in understanding of the pathophysiological functions of CaCC ANO1 and the current modulators used as pharmacological tools,hopefully illustrating a broad spectrum of ANO1 channelopathy and a path forward for this target validation.

关 键 词：Ca^(2+)-activated Cl^(-)channels(CaCCs) ANO1 TMEM16A CaCCinh-A01 T16Ainh-A01 Drug target Cancer Cystic fibrosis 

分 类 号：R363[医药卫生—病理学]